Accelerated Medical Diagnostics LLC Profile last edited on: 11/15/2019
CAGE: 549U4
UEI: JWEZE9VNHL14
Business Identifier: Personalizing chemotherapy with diagnostic microdosing 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
957 Hilldale Avenue
Berkeley, CA 94708
Berkeley, CA 94708
Location: Single
Congr. District: 12
County: Alameda
Congr. District: 12
County: Alameda
Public Profile
Accelerated Medical Diagnostics, Inc., is a cancer diagnostics company bringing together expertise in cancer biology, chemotherapy drugs and diagnostics to develop objective, reproducible tests designed to provide clinicians with information to enhance patient care. Early in the field of predictive chemotherapy diagnostics, the firm is stucrured around developing clinically validated tests that empower clinicians better to tailor care to each individual patient. In collaborations with university hospitals - UC Davis and UCSF - Accelerated Medical Diagnostics is currently conducting a retrospective clinical trial. The firm is strategically focused on induction chemotherapy for acute myeloid leukemia (AML) and close to commercialization of the firm's test - InductDx - that enables measurement of cellular responses to nontoxic microdoses of chemotherapy administered to cells derived from patient blood samples.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2017 | 1 | NIH | $299,999 | |
| Project Title: Feasibility of predicting AML response to induction chemotherapy | ||||
| 2012 | 2 | NIH | $1,695,444 | |
| Project Title: Phase 0 Carboplatin Microdosing Diagnostics Trial | ||||
| 2012 | 1 | NIH | $199,969 | |
| Project Title: Other Functions - R&D Biomedical (Basic Research) | ||||
Key People / Management
Paul T Henderson -- Chief Executive Officer
George Cimino -- VP of Development & CFO
William Hope -- Financial Consultant
Chong-Xian Pan -- Co Founder
Neil Thompson -- Board of Directors
Maike Zimmerman -- Postdoctoral Fellow
George Cimino -- VP of Development & CFO
William Hope -- Financial Consultant
Chong-Xian Pan -- Co Founder
Neil Thompson -- Board of Directors
Maike Zimmerman -- Postdoctoral Fellow
